SG11202112951TA - Detection of antibodies to sarsr-cov - Google Patents

Detection of antibodies to sarsr-cov

Info

Publication number
SG11202112951TA
SG11202112951TA SG11202112951TA SG11202112951TA SG11202112951TA SG 11202112951T A SG11202112951T A SG 11202112951TA SG 11202112951T A SG11202112951T A SG 11202112951TA SG 11202112951T A SG11202112951T A SG 11202112951TA SG 11202112951T A SG11202112951T A SG 11202112951TA
Authority
SG
Singapore
Prior art keywords
sarsr
cov
antibodies
detection
Prior art date
Application number
SG11202112951TA
Other languages
English (en)
Inventor
Linfa Wang
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG11202112951TA publication Critical patent/SG11202112951TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202112951TA 2020-03-25 2021-03-24 Detection of antibodies to sarsr-cov SG11202112951TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202002784P 2020-03-25
SG10202004468Q 2020-05-14
PCT/SG2021/050164 WO2021194423A1 (en) 2020-03-25 2021-03-24 Detection of antibodies to sarsr-cov

Publications (1)

Publication Number Publication Date
SG11202112951TA true SG11202112951TA (en) 2021-12-30

Family

ID=72290786

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112951TA SG11202112951TA (en) 2020-03-25 2021-03-24 Detection of antibodies to sarsr-cov

Country Status (8)

Country Link
US (2) US11112412B1 (pt)
EP (1) EP3800473A1 (pt)
KR (1) KR102443389B1 (pt)
CN (2) CN111983226A (pt)
BR (1) BR102021005055B1 (pt)
DE (1) DE202020005492U1 (pt)
SG (1) SG11202112951TA (pt)
WO (1) WO2021194423A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021205866A1 (en) * 2020-01-09 2022-09-08 The University Of Queensland Self-assembling, self-adjuvanting system for delivery of vaccines
US20220002700A1 (en) * 2020-04-03 2022-01-06 Massachusetts Institute Of Technology COMPUTATIONALLY-OPTIMIZED ACE2 PEPTIDES FOR COMPETITIVE INTERCEPTION OF SARS-CoV-2
EP4136460A2 (en) * 2020-04-13 2023-02-22 Abbott Laboratories Methods and kits for detecting or determining an amount of an anti-b-coronavirus antibody in a sample
WO2021211331A1 (en) * 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021214467A1 (en) * 2020-04-23 2021-10-28 Cellbio A diagnostic tool improvement comprising a pathogen binding molecule
CN113624977A (zh) * 2020-05-09 2021-11-09 中国科学技术大学 SARS-CoV-2感染诊断方法
CN113419061B (zh) * 2020-06-19 2022-02-01 南京金斯瑞生物科技有限公司 检测SARS-CoV-2病毒中和抗体的磁微粒化学发光试剂盒及其应用
EP4182689A2 (en) * 2020-07-15 2023-05-24 Diazyme Laboratories, Inc. Compositions and methods for assaying neutralizing antibodies
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
WO2022027088A1 (en) * 2020-08-03 2022-02-10 The University Of Melbourne Lateral flow device and uses thereof
WO2022123470A1 (en) * 2020-12-10 2022-06-16 Reagene Biosciences Pvt. Ltd. Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies
US11693011B2 (en) 2020-12-14 2023-07-04 Inbios International, Inc. Neutralizing antibody immunoassays
CN112881706B (zh) * 2021-01-12 2022-06-03 广东菲鹏生物有限公司 一种同时检测总抗体和中和抗体的方法
CN112904018B (zh) * 2021-01-19 2022-03-01 深圳秀朴生物科技有限公司 一种检测病毒中和抗体的试剂盒、方法和用途
WO2022159834A1 (en) * 2021-01-22 2022-07-28 La Jolla Institute For Immunology Chimeric anti-coronavirus spike protein antibodies
CN114878823A (zh) * 2021-02-05 2022-08-09 广东菲鹏生物有限公司 一种抗体检测方法
CN114672474B (zh) * 2021-02-24 2023-07-04 中国科学院生物物理研究所 一种ace2突变体及其突变方法和应用
EP4314821A1 (en) * 2021-03-31 2024-02-07 Randox Laboratories Ltd. Coronavirus assay
WO2022211558A1 (ko) * 2021-04-01 2022-10-06 (주)셀트리온 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자
US20240192214A1 (en) * 2021-04-20 2024-06-13 The Trustees Of The University Of Pennsylvania Color: a low-cost optodiagnostic for sars-cov-2
US11513097B1 (en) 2021-05-21 2022-11-29 PERSOWN, Inc. Methods of obtaining and using electrochemical diagnostic results
WO2022246292A1 (en) 2021-05-21 2022-11-24 PERSOWN, Inc. Electrochemical diagnostic system and methods of obtaining and using electrochemical diagnostic results
WO2022253260A1 (zh) * 2021-06-01 2022-12-08 南京金斯瑞生物科技有限公司 新型冠状病毒及其突变株中和抗体的检测试剂盒
CN113484522B (zh) * 2021-06-03 2022-05-10 上海捷诺生物科技有限公司 SARS-CoV-2中和抗体检测试剂盒及其制备方法
CN113603769A (zh) * 2021-07-20 2021-11-05 贵州省人民医院 一种稳定分泌抗新型冠状病毒核衣壳蛋白单克隆抗体的杂交瘤细胞株及其建立方法和应用
WO2023004415A2 (en) * 2021-07-22 2023-01-26 University Of Miami Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
KR20230015063A (ko) * 2021-07-22 2023-01-31 주식회사 미코바이오메드 코로나바이러스 중화항체 진단용 래피드 키트
EP4124865A1 (en) 2021-07-28 2023-02-01 Friedrich-Alexander-Universität Erlangen-Nürnberg A surrogate cell-based corona virus spike protein blocking assay
CN113341145A (zh) * 2021-07-28 2021-09-03 瑞博奥(广州)生物科技股份有限公司 一种s1f-axl复合物、试剂盒和检测该复合物的方法及应用
WO2023043213A2 (ko) * 2021-09-16 2023-03-23 한장현 안지오텐신전환효소 2 수용체 및 이의 용도
WO2023056143A1 (en) * 2021-09-30 2023-04-06 Siemens Healthcare Diagnostics Inc. Compositions, kits, and methods for duplex immunoassay for anti-sars-cov-2 antibodies
WO2023073672A1 (en) * 2021-10-29 2023-05-04 Geneone Life Science, Inc. Therapeutic and vaccine candidates against sars-cov-2
CN114075553B (zh) * 2021-10-30 2023-10-03 西北工业大学 一种可用于新冠病毒中和抗体活性评价和作为核酸检测标准物的假病毒颗粒及其制备方法
CN114231497B (zh) * 2022-02-24 2022-05-20 广州伯尼兹生物科技有限公司 一株表达SARS-CoV-2 S1蛋白单克隆抗体杂交瘤细胞系及中和活性抗体
CN114740199A (zh) * 2022-03-18 2022-07-12 北京安奇生物医药科技有限公司 一种SARS-CoV-2中和抗体试剂盒及其应用
CN115028715B (zh) * 2022-06-23 2023-08-18 生工生物工程（上海）股份有限公司 一种抗新型冠状病毒的抗体或其抗原结合片段、试剂盒及应用
CN116041494A (zh) * 2022-12-12 2023-05-02 首都医科大学 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032487A2 (en) 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
WO2005120565A2 (en) 2004-06-02 2005-12-22 New York Blood Center Sars vaccines and methods to produce highly potent antibodies
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
BRPI0606148A2 (pt) 2005-02-08 2009-06-02 New York Blood Ct Inc anticorpos monoclonais neutralizantes contra a sìndrome respiratória aguda grave associada com o coronavìrus
US20070190065A1 (en) * 2005-06-03 2007-08-16 Ralf Altmeyer Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
NZ568386A (en) 2005-12-12 2011-08-26 Innova Biosciences Ltd Production of conjugates using a thiol generator
AT504443B1 (de) * 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
CN102015767A (zh) 2008-01-17 2011-04-13 胡马斯有限公司 针对SARS-CoV的交叉中和人单克隆抗体及其使用方法
WO2015057666A1 (en) * 2013-10-14 2015-04-23 The University Of North Carolina At Chapel Hill Methods and compositions for coronavirus diagnostics and therapeutics
WO2015066259A1 (en) * 2013-10-31 2015-05-07 Regeneron Pharmaceuticals, Inc. Competitive ligand binding assay for detecting neutralizing antibodies
MX2019002818A (es) * 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
CN108776231B (zh) * 2018-09-06 2020-12-29 长沙文瀚生物技术有限责任公司 一种人尿白蛋白胶乳增强二抗竞争免疫比浊检测试剂盒及其制作和使用方法
CN111273016B (zh) * 2020-02-26 2021-06-15 浙江诺迦生物科技有限公司 一种基于s蛋白配体与ace2受体竞争法层析的冠状病毒快速检测的试剂盒

Also Published As

Publication number Publication date
KR20220024452A (ko) 2022-03-03
US20210302434A1 (en) 2021-09-30
EP3800473A1 (en) 2021-04-07
CN114258490A (zh) 2022-03-29
KR102443389B1 (ko) 2022-09-14
US11054429B1 (en) 2021-07-06
DE202020005492U1 (de) 2021-08-06
US11112412B1 (en) 2021-09-07
BR102021005055A2 (pt) 2021-06-22
CN111983226A (zh) 2020-11-24
BR102021005055B1 (pt) 2022-05-31
WO2021194423A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
SG11202112951TA (en) Detection of antibodies to sarsr-cov
EP3679397A4 (en) TIME ALIGNMENT OF MOTION DETECTION SIGNALS USING BUFFERS
HK1211223A1 (en) Human monoclonal anti-pd-l1 antibodies and methods of use -pd-l1
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
LT2734551T (lt) Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
SG11201505192RA (en) Chromatographic purification of antibodies from chromatin-deficient cell culture harvests
HK1218297A1 (zh) 用於生產單克隆抗體的改進方法
EP3286334A4 (en) Method to increase sensitivity of next generation sequencing
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EP3966248A4 (en) HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
EP3746123A4 (en) ANTIBODIES TO GALECTIN-3 AND METHOD OF USING THEREOF
HK1257199A1 (zh) 用於檢測cd37的抗體和測定
IL283136A (en) Antibodies to mucin-16 and methods of using them
EP4061852A4 (en) ANTIBODIES TARGETED TO TIE-2 AND METHODS OF USE
FI20135750A (fi) Hydrofobiinien ja vasta-aineiden konsentrointi ja puhdistus faasierotusmenetelmällä
HK1249420A1 (zh) 使用針對母源腦反應性抗體的誘餌抗原抑制孤獨症譜系障礙
GB2599034B (en) Methods to improve detection of glycosylamines
EP3910547C0 (de) Erfassung von bewegten objekten
GB202012434D0 (en) Multiomic analysis of nanoparticle-coronas
GB201909491D0 (en) Detection of protein to protein interactions
EP4078364A4 (en) MIGRATION FROM VNF TO VIM
IL272015A (en) Antibodies to MADCAM
GB202107330D0 (en) Antibodies to GFRAL
GB202104553D0 (en) Antibodies to GFRAL
GB201701707D0 (en) Improvements to operations of engines